JAMA Network
About The Study: In this meta-analysis, nirsevimab was associated with reduced lower respiratory tract infection-related hospitalizations and emergency department visits in infants and young children. These findings support nirsevimab's potential to reduce respiratory-related morbidity in young children and health care utilization.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
